News & Insights
All the latest News and Insights from OHE, plus an archive of our monthly email bulletin.
Latest Insights
How long are patients WAITing for new treatments?
The latest EFPIA Patients W.A.I.T. Indicator 2025 Survey shows that patients across Europe are waiting longer for access to new medicines, with major differences between countries. Here we explain how to interpret the W.A.I.T indicators.
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
Much of the Most-Favoured-Nation debate asks whether the United States can persuade other countries to pay more for medicines. Germany is the market where that question is hardest to answer and where it matters most.
The cost of inaction on LDL cholesterol
This Insight is based on the WHA79 panel discussion “Lowering Cholesterol, Increasing Impact: The Case for Earlier Action to Address the CV Epidemic”, co-organised by OHE and MSD, at the World Health Assembly in Geneva, May 2026.
Latest News
OHE Deputy CEO Lotte Steuten appointed president-elect of ISPOR
OHE Deputy Chief Executive Lotte Steuten has been appointed to the role of president-elect of ISPOR.
OHE responds to the King’s Speech and the proposed NHS Modernisation Bill
Commenting on the King’s Speech today and the proposed NHS Modernisation Bill, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “Today’s King’s Speech…
Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds
The research also provides detailed, country-level insights into the health and economic costs of ASCVD across the US, Canada, UK, Netherlands, France, Germany, Spain, Italy, and Japan.
OHE responds to the 2025 UK Budget
Commenting on the newly announced 2025 UK Budget, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The NHS’ long-term sustainability will only come…
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
Today, the Acute Leukemia Advocates Network (ALAN) and the Office of Health Economics (OHE published a first-of-its-kind qualitative study of informal carers across 6 countries.
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
Latest Podcasts
Prevention works, so why don’t we pay for it?
Grace Hampson is joined by Gundo Weiler, Director of Prevention and Health Promotion at the World Health Organization (WHO) Regional Office for Europe, and Graham Cookson,…
Can HTA keep up with innovation?
But the pace of innovation often outruns policy – new developments in innovative therapies, digital health technologies, and a shifting geopolitical landscape are pushing HTA systems…
Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number
Grace Hampson is joined by Adrian Towse, who ran OHE as its Director for many years, and Chris Sampson, Senior Principal Economist at OHE, to dig into one…
